Amidst Rise in Co-Occurring Disorders, Ammon Labs Introduces New Antipsychotic Testing Panel

New testing panel will enable toxicology lab to better serve addiction treatment and mental health community

 Linden, N.J. (November 15, 2018) – Ammon Labs announces the introduction of a new testing panel designed to more effectively test for antipsychotic medication. Ammon Labs’ new testing panel will allow the lab to determine if clients are taking prescribed antipsychotic medication in accordance with their doctor’s guidelines. This data will better inform addiction treatment providers’ course of treatment when working with individuals with co-occurring mental health and substance use disorders.

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), over 7.9 million American adults are currently living with co-occurring substance use and mental health disorders. The complex relationship between mental health and addiction for someone with a co-occurring disorder can often make addiction treatment difficult, leading to decreased efficacy. As many patients in this population are often taking both prescribed medication and illicit substances, it is vitally important that addiction treatment providers have accurate and reliable information about all medication in their clients’ systems to better tailor their individual substance abuse treatment.

“The newly developed and approved testing panel for psychiatric medications will greatly enhance treatment providers’ ability to monitor and document use of those prescribed medications,” said Dr. Louis Baxter, Director of Testing in Addiction Medicine for Ammon Labs. “In a general sense, prescribed medication only works if it is being properly taken. Having these tests available will provide a means to verify and document this important concern in treatment for our patients with substance use disorders and co-occurring mental health disorders.  Ammon Labs’ commitment to substance use disorder recovery, and now the monitoring of psychiatric medications, gives practitioners and patients another advantage in supporting and advancing the medical care for this population.”

Ammon Labs’ new testing panel includes testing for the following drugs:

  • Aripiprazole (Abilify) + metabolites (Dehydro Aripiprazole/OPC-3373)
  • Chlorpromazine (Thorazine/Largactil)
  • Clozapine (Clozaril) + metabolite (N-Desmethylclozapine)
  • Fluphenazine (Prolixin)
  • Haloperidol (Haldol)
  • Lurasidone (Latuda)
  • Olanzapine (Zyprexa) + metabolite (N-Desmethylolanzapine)
  • Promethazine (Phenergan)
  • Quetiapine (Seroquel) + metabolites (7-Hydroxyquetiapine/Norquetiapine/Quetiapine Carboxylic Acid)
  • Risperidone (Risperdal) + metabolite (9-Hydroxyrisperidone)
  • Trifluoperazine (Stelazine)
  • Ziprasidone (Geodon)

Alejandro Amador, COO of Ammon Labs added, “Ammon Labs is deeply committed to providing our clients with the most up-to-date and reliable testing panels to ensure they have the data they need to properly treat everyone under their care. The introduction of our latest testing panel speaks to this commitment and we look forward to working with our partners to continue to identify and create the tools they need to provide the best level of care.”

For more information on Ammon Labs’ testing services, please contact Ammon Labs at 908-862-4404.

2018-11-14T18:55:27+00:00